# Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

> **NCT03899077** · PHASE2 · UNKNOWN · sponsor: **Cancer Research Antwerp** · enrollment: 202 (estimated)

## Conditions studied

- Cancer of Prostate

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial
- **DRUG:** Goserelin Acetate 10.8 MG Subcutaneous Implant
- **DRUG:** Triptorelin Pamoate
- **DRUG:** Degarelix acetate

## Key facts

- **NCT ID:** NCT03899077
- **Lead sponsor:** Cancer Research Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-05
- **Primary completion:** 2025-08
- **Final completion:** 2025-12
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899077, "Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03899077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*